 Desensitization, Immunologic
"Desensitization, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity.
| Descriptor ID |
D003888
|
| MeSH Number(s) |
E02.095.465.425.450.310 E05.478.610.310
|
| Concept/Terms |
Desensitization, Immunologic- Desensitization, Immunologic
- Immunologic Desensitization
- Desensitizations, Immunologic
- Immunologic Desensitizations
- Therapy, Hyposensitization
- Hyposensitization Therapies
- Therapies, Hyposensitization
- Hyposensitization Therapy
Allergen Immunotherapy- Allergen Immunotherapy
- Allergen Immunotherapies
- Immunotherapies, Allergen
- Immunotherapy, Allergen
|
Below are MeSH descriptors whose meaning is more general than "Desensitization, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Desensitization, Immunologic".
This graph shows the total number of publications written about "Desensitization, Immunologic" by people in this website by year, and whether "Desensitization, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 | | 1995 | 0 | 2 | 2 | | 1997 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 2 | 0 | 2 | | 2010 | 4 | 1 | 5 | | 2011 | 1 | 0 | 1 | | 2012 | 4 | 1 | 5 | | 2013 | 5 | 0 | 5 | | 2014 | 6 | 0 | 6 | | 2015 | 1 | 1 | 2 | | 2016 | 6 | 2 | 8 | | 2017 | 2 | 0 | 2 | | 2018 | 7 | 1 | 8 | | 2019 | 6 | 2 | 8 | | 2020 | 9 | 4 | 13 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Desensitization, Immunologic" by people in Profiles.
-
Wasserman RL, Factor J, Windom HH, Abrams EM, Begin P, Chan ES, Greenhawt M, Hare N, Mack DP, Mansfield L, Ben-Shoshan M, Stukus DR, Leek TV, Shaker M. An Approach to the Office-Based Practice of Food Oral Immunotherapy. J Allergy Clin Immunol Pract. 2021 05; 9(5):1826-1838.e8.
-
Remington BC, Campbell DE, Green TD, Fleischer DM, Koppelman SJ. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. Ann Allergy Asthma Immunol. 2021 02; 126(2):208-209.
-
Brar KK, Lanser BJ, Schneider A, Nowak-Wegrzyn A. Biologics for the Treatment of Food Allergies. Immunol Allergy Clin North Am. 2020 11; 40(4):575-591.
-
DunnGalvin A, Fleischer DM, Campbell DE, O'B Hourihane J, Green TD, Sampson HA, Greenhawt M. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. J Allergy Clin Immunol Pract. 2021 01; 9(1):216-224.e1.
-
Fleischer DM, Shreffler WG, Campbell DE, Green TD, Anvari S, Assa'ad A, Bégin P, Beyer K, Bird JA, Brown-Whitehorn T, Byrne A, Chan ES, Cheema A, Chinthrajah S, Chong HJ, Davis CM, Ford LS, Gagnon R, Greenhawt M, Hourihane JO, Jones SM, Kim EH, Lange L, Lanser BJ, Leonard S, Mahler V, Maronna A, Nowak-Wegrzyn A, Oriel RC, O'Sullivan M, Petroni D, Pongracic JA, Prescott SL, Schneider LC, Smith P, Staab D, Sussman G, Wood R, Yang WH, Lambert R, Peillon A, Bois T, Sampson HA. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020 10; 146(4):863-874.
-
Abrams EM, Brough HA, Keet C, Shaker MS, Venter C, Greenhawt M. Pros and cons of pre-emptive screening programmes before peanut introduction in infancy. Lancet Child Adolesc Health. 2020 07; 4(7):526-535.
-
Fleischer DM, Chinthrajah S, Scurlock AM, Campbell DE, Green TD, Bee KJ, Peillon A, Ocheltree T, Sampson HA. An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial. Allergy Asthma Proc. 2020 09 01; 41(5):326-335.
-
Kim EH, Perry TT, Wood RA, Leung DYM, Berin MC, Burks AW, Cho CB, Jones SM, Scurlock A, Sicherer SH, Henning AK, Dawson P, Lindblad RW, Plaut M, Sampson HA. Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. J Allergy Clin Immunol. 2020 10; 146(4):851-862.e10.
-
Fleischer DM, Spergel JM, Kim EH, Campbell DE, Green TD, Bee KJ, Lambert R, Ocheltree T, Sampson HA. Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy. Allergy Asthma Proc. 2020 07 01; 41(4):278-284.
-
Greenhawt M, Kim EH, Campbell DE, Green TD, Lambert R, Fleischer DM. Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years. J Allergy Clin Immunol Pract. 2020 10; 8(9):3219-3221.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|